← Leaderboards
Peter B. Gilbert
Fred Hutchinson Cancer Center
$223,972,501
Attributed
$364,585,145
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $50.4M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$364,585,145 · 4
By mechanism
UM1$355,053,837 · 1
R37$6,247,692 · 1
R01$3,283,616 · 2
Top collaborators
- Yunda Huang28 shared
- Holly Janes27 shared
- Carolyn Williamson5 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Yunda Huang$75,372,842
- Holly Janes$70,932,400
- Margaret Juliana McElrath$601,692,649
- Lawrence Corey$859,232,520
- Georgia D Tomaras$127,423,185
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesDesignInfectionImmune ResponseEfficacy TrialImmuneHiv Vaccine Trials NetworkHiv VaccinePreventionClinical TrialsPreventVaccine TrialVaccinationVaccine EfficacyProgramsLeadershipProtocols DocumentationLaboratoriesImmunityBiometrySamplingSiteGeneticSafety
Grant awards (70)
SDMC: HIV Vaccine Trials Network$35,817,302
UM1 · FY2025 · AI · contact PI
SDMC: HIV Vaccine Trials Network$4,411,693
UM1 · FY2025 · AI · contact PI
SDMC: HIV Vaccine Trials Network$992,886
UM1 · FY2025 · AI · contact PI
SDMC: HIV Vaccine Trials Network$991,756
UM1 · FY2025 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$498,210
R37 · FY2025 · AI · contact PI
SDMC: HIV Vaccine Trials Network$31,992,488
UM1 · FY2024 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$536,488
R37 · FY2024 · AI · contact PI
B Cell Bioinformatic Supplement: HIV Vaccine Trials Network (HVTN)$330,961
UM1 · FY2024 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$327,638
R01 · FY2024 · AI
SDMC: HIV Vaccine Trials Network$28,510,098
UM1 · FY2023 · AI · contact PI
CoVPN 3008 2022-2023$12,647,369
UM1 · FY2023 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$427,112
R37 · FY2023 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$333,359
R01 · FY2023 · AI
SDMC: HIV Vaccine Trials Network$21,460,272
UM1 · FY2022 · AI · contact PI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$14,844,618
UM1 · FY2022 · AI · contact PI
SDMC: HIV Vaccine Trials Network$5,436,127
UM1 · FY2022 · AI · contact PI
CoVPN Cross-Protocol Analyses$1,846,794
UM1 · FY2022 · AI · contact PI
CoVPN Cross-Protocol Analyses$1,334,886
UM1 · FY2022 · AI · contact PI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$1,011,819
UM1 · FY2022 · AI · contact PI
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection$818,451
UM1 · FY2022 · AI · contact PI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$477,868
UM1 · FY2022 · AI · contact PI
CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$453,649
UM1 · FY2022 · AI · contact PI
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.$439,437
UM1 · FY2022 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$426,899
R37 · FY2022 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older$419,442
UM1 · FY2022 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$336,419
R01 · FY2022 · AI
CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19$318,803
UM1 · FY2022 · AI · contact PI
HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals$293,711
UM1 · FY2022 · AI · contact PI
CoVPN 3003 - A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$260,795
UM1 · FY2022 · AI · contact PI
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults$234,860
UM1 · FY2022 · AI · contact PI
SDMC: HIV Vaccine Trials Network$26,398,527
UM1 · FY2021 · AI · contact PI
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$18,322,345
UM1 · FY2021 · AI · contact PI
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$2,034,708
UM1 · FY2021 · AI · contact PI
CoVPN Cross-Protocol Analyses$1,367,342
UM1 · FY2021 · AI · contact PI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$673,501
UM1 · FY2021 · AI · contact PI
CoVPN Cross-Protocol Analyses$589,642
UM1 · FY2021 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$340,958
R01 · FY2021 · AI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$248,674
R37 · FY2021 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$178,322
R37 · FY2021 · AI · contact PI
SDMC: HIV Vaccine Trials Network$21,423,906
UM1 · FY2020 · AI · contact PI
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC$1,414,274
UM1 · FY2020 · AI · contact PI
Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens$466,074
R37 · FY2020 · AI · contact PI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$401,609
UM1 · FY2020 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$348,710
R01 · FY2020 · AI
SDMC: HIV Vaccine Trials Network$21,276,122
UM1 · FY2019 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$368,459
R37 · FY2019 · AI · contact PI
SDMC: HIV Vaccine Trials Network$21,055,904
UM1 · FY2018 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$368,492
R37 · FY2018 · AI · contact PI
SDMC: HIV Vaccine Trials Network$16,985,420
UM1 · FY2017 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$368,845
R37 · FY2017 · AI · contact PI
SDMC: HIV Vaccine Trials Network$10,940,011
UM1 · FY2016 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$369,201
R37 · FY2016 · AI · contact PI
SDMC: HIV Vaccine Trials Network$13,241,799
UM1 · FY2015 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$406,438
R37 · FY2015 · AI · contact PI
SDMC: HIV Vaccine Trials Network$10,240,739
UM1 · FY2014 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$310,485
R37 · FY2014 · AI · contact PI
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network$5,995,463
UM1 · FY2013 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$292,871
R37 · FY2013 · AI · contact PI
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network$8,628,364
UM1 · FY2012 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$311,664
R37 · FY2012 · AI · contact PI
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network$8,718,076
UM1 · FY2011 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$313,632
R37 · FY2011 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$355,826
R37 · FY2010 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$229,738
R01 · FY2009 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$230,272
R01 · FY2008 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$235,258
R01 · FY2007 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$277,369
R01 · FY2006 · AI · contact PI
Statistical Methods in HIV Vaccine Efficacy Trials$203,579
R01 · FY2005 · AI
Statistical Methods in HIV Vaccine Efficacy Trials$204,066
R01 · FY2004 · AI
Statistical Methods in HIV Vaccine Efficacy Trials$216,250
R01 · FY2003 · AI